miR-203 improves pressure overload-induced heart failure by targeting the IGFBP5/PI3K/AKT axis

Area of Science:

• Cardiovascular Biology
• Molecular Medicine
• Genetics

Background:

• Heart failure (HF) is a severe cardiovascular disease with high mortality.
• Pressure overload triggers the PI3K/AKT pathway, leading to pathological cardiac hypertrophy in HF.
• The precise mechanisms sustaining PI3K/AKT activation in pressure overload-induced HF are not fully understood.

Purpose of the Study:

• To investigate the role of microRNA-203 (miR-203) in pressure overload-induced heart failure.
• To elucidate the molecular mechanisms by which miR-203 regulates cardiac hypertrophy and dysfunction.

Main Methods:

• Utilized transgenic mice with altered miR-203 expression to model pressure overload-induced HF.
• Employed cell culture experiments with Angiotensin II stimulation to assess cardiomyocyte hypertrophy and injury.
• Performed molecular analyses including mRNA and protein expression studies, and 3'UTR binding assays.

Main Results:

• Overexpression of miR-203 ameliorated cardiac dysfunction and pathological remodeling in HF models.
• Downregulation of miR-203 exacerbated HF phenotypes.
• miR-203 directly targets insulin-like growth factor binding protein 5 (IGFBP5) mRNA, inhibiting its protein expression and suppressing the PI3K/AKT pathway.
• Fibronectin-1 (FN1) was identified as a functional partner of IGFBP5, mediating its pro-hypertrophic effects.

Conclusions:

• miR-203 plays a protective role in pressure overload-induced heart failure.
• The miR-203/IGFBP5/PI3K/AKT axis is a key regulator of cardiac hypertrophy.
• miR-203 represents a novel therapeutic target for heart failure treatment.